P3.18.39 PRESERVE-003: A Phase 3 Study of Gotistobart Versus Docetaxel in Metastatic NSCLC After Progression on PD-(L)1 Inhibitors
Year: 2025
Type: article
Source: Journal of Thoracic Oncology
Authors: T. Li, Y. Wu, B.C. Cho, R. Balaraman, H-J. Chen, A. Fawole, X. Yu, Z-g. Liu, J. Zhang, J. Hamm, W. Long, B. Yang, J. Leddon, Y. Huang, P. Pan, S. Shpyro, Q. Wang, P. Zheng, Y. Liu, S. Efuni, K. He, M.A. Socinski
Institutions: UC Davis Comprehensive Cancer Center, Florida Cancer Specialists & Research Institute, Zhejiang Cancer Hospital, Dongguan People’s Hospital, Southern Medical University, Chengdu Seventh People's Hospital, Norton Healthcare, Wuhan University, Renmin Hospital of Wuhan University, Hubei Cancer Hospital, University of Cincinnati, Hainan General Hospital, Xiangya Hospital Central South University, BioNTech (Germany), The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University Wexner Medical Center, The Ohio State University, AdventHealth Orlando
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W4415520068